Amisulpride (DAN-2163)

Amisulpride is an atypical antipsychotic used to treat psychosis in schizophrenia and episodes of mania in bipolar disorder. In Italy, it is also used as a treatment for dysthymia. It was introduced by Sanofi-Aventis in the 1990s. Its patent had expired by 2008 and hence generic formulations are now available.Amisulpride function primarily as a D2 and D3 receptor antagonist. It has high affinity for these receptors with dissociation constants of 2.2 nM and 2.4 nM, respectively. Although standard doses used to treat psychosis inhibit dopaminergic neurotransmission, low doses preferentially block inhibitory pre-synaptic autoreceptors.

Properties:
Appearance & Physical State: White or almost white crystalline powder
Density: 1.2 g/cm3
Boiling Point: 558.9ºC at 760 mmHg
Melting Point: 124-128ºC
Flash Point: 291.8ºC
Refractive Index: 1.545

Dopamine Receptor Inhibitors Related Products:

Ropinirole hydrochloride; Quetiapine fumarate; Domperidone; Paliperidone; ONC206; Sulpiride; SKF-38393 HCl

[1]. Schoemaker H, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997 Jan;280(1):83-97.

[2]. Pawar GR, et al. Evaluation of antidepressant like property of amisulpride per se and its comparison with fluoxetine and olanzapine using forced swimming test in albino mice. Acta Pol Pharm. 2009 May-Jun;66(3):327-31.